english.prescrire.org > Spotlight > Archives : 2024 > Solifenacin + tamsulosin (Vecalmys°/Vesomni°) in benign prostatic hyperplasia: not acceptable

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2024 : 1 | 30 | 60

Solifenacin + tamsulosin (Vecalmys°/Vesomni°) in benign prostatic hyperplasia: not acceptable

 Marketing Authorisations   A fixed-dose combination of the antimuscarinic drug solifenacin and the alpha-1 blocker tamsulosin has been authorised in France and some other European countries to relieve the symptoms of benign prostatic hyperplasia when monotherapy (of any kind) has been considered insufficiently effective.
Full article available for download by subscribers

EDITORS' OPINION
Absurd!

It has long been known that by blocking the parasympathetic nervous system of the bladder, antimuscarinic drugs can cause problems with urination, and in some cases urinary retention...

Full text available for download by subscribers

©Prescrire 1 October 2024

Source: "Solifenacin + tamsulosin (Vecalmys°) in benign prostatic hyperplasia" Prescrire Int 2024; 33 (263): 238-239. Subscribers only.

Enjoy full access to Prescrire International, and support independent information